A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin
Part of paid clinical trials in Las Vegas, Nevada.
- Sponsor
- Rejuvaskin
- Study ID
- NCT07700745
- Status
- Active Not Recruiting
Conditions
- Atopic Dermatitis
- Eczema
- Eczema-Prone Skin
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rejuvaskin Eczema Body Wash — DIETARY_SUPPLEMENTParticipants use Rejuvaskin Eczema Body Wash once daily during a shower or bath in place of their usual body cleanser, followed by application of Rejuvaskin Skin Recovery Cream, for 4 consecutive weeks.
Study Details
This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Participants will use the body wash once daily in place of their usual cleanser, followed by the Skin Recovery Cream, for 4 consecutive weeks.
Key Dates
- First listed
- Jul 14, 2026
- Start date
- Jul 6, 2026
- Status verified
- Jul 2026
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2026
Study Design
- Enrollment
- 35 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Rejuvaskin Eczema Body Wash Arm
Primary Outcome Measure
Change from Baseline in Self-Reported Skin Dryness [ Time Frame: Baseline to Week 4 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Citruslabs | Las Vegas | Nevada | 89118 | - |
Find similar trials in Las Vegas, NV
Nationwide
By condition
By specialty
By research site
Related Studies
- A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabPHASE3 · Recruiting · AbbVie · Birmingham, Alabama
- Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & AdultsRecruiting · Galderma R&D · Phoenix, Arizona
- A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisPHASE3 · Recruiting · Organon and Co · Birmingham, Alabama
- This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic TreatmentRecruiting · Sanofi · Birmingham, Alabama